FDA Approves Pneumonia Treatment

News
Article

The agency approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia.

On Aug. 19, 2019, FDA announced it has approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia (CABP). Xenleta was approved after receiving Qualified Infectious Disease Product designation for products designed to treat serious, life-threatening infections.

According to FDA, community-acquired pneumonia develops outside of a hospital setting and can range from severe to mild. Approximately 50,000 people die from CABP and one million people are hospitalized with the infection each year in the United States.

Xenleta was evaluated in two clinical trials with a total of 1289 patients with CABP, which compared the drug to moxifloxacin with or without linezolid. Patients treated with Xenleta had similar rates of clinical success as those treated with moxifloxacin with or without linezolid, according to FDA. Common adverse reactions include diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and vomiting. 

The agency advises that there are risks involved when taking the new medication. “Xenleta has the potential to cause a change on an ECG reading (prolonged QT interval). Patients with prolonged QT interval, patients with certain irregular heart rhythms (arrhythmias), patients receiving treatment for certain irregular heart rhythms (antiarrhythmic agents), and patients receiving other drugs that prolong the QT interval should avoid Xenleta,” FDA stated in a press release. Patients with a known hypersensitivity to lefamulin or any other members of the pleuromutilin antibiotic class, or any of the components of Xenleta, should not use Xenleta. The agency also advises that pregnant women and women who could become pregnant should be advised of the risks of using Xenleta.

“This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease,” said Ed Cox, MD, MPH, director of FDA’s Office of Antimicrobial Products, in the press release. “For managing this serious disease, it is important for physicians and patients to have treatment options. This approval reinforces our ongoing commitment to address treatment of infectious diseases by facilitating the development of new antibiotics.”

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content